

Form PTO-1449		Attorney's Docket No. <b>39780-1618P2C46</b>	Application Serial No. <b>09/903,520</b>				
O I P INFORMATION DISCLOSURE STATEMENT <i>(use several sheets if necessary)</i>		Applicant(s) <b>ASHKENAZI, et al.</b>					
		Filing Date: <b>July 11, 2001</b>	Group Art Unit: <b>1646</b>				
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
<b>NJH</b>	1.	8/21/90	4,950,647	Robins et al.			10/4/88
	2.	7/15/97	5,648,376	Strobel et al.			1/19/95
	3.	9/1/98	5,801,193	Ojo-Amaize et al.			4/15/97
	4.	10/6/98	5,817,306	Haskill et al.			6/7/95
	5.	09/28/99	5,958,403	Storm, et al.			
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES      NO
<b>OTHER DOCUMENTS</b> <i>(including author, title, date, pertinent pages, etc.)</i>							
Examiner Initials	Ref. No.	Title					
<b>NJH</b>	6.	Abolhassani, M., "Antibacterial effect of borage ( <i>Echium amoenum</i> ) on <i>Staphylococcus aureus</i> ," <i>Brazilian Journal of Infectious Diseases</i> 8:382-385 (2004).					
	7.	Amirghofran, Z. et al., " <i>Echium amoenum</i> stimulate of lymphocyte proliferation and inhibit fo humoral antibody synthesis," <i>Im. J. Med. Sci.</i> 25:119-124 (2000).					
	8.	Chapoval, A. I. et al., "Combination chemotherapy and IL-15 administration induces permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells," <i>J. Immunol.</i> 161:6977-6984 (1998).					
	9.	Fung-Leung, et al., "Tepoxalin, A Novel Immunomodulatory Compound, Synergizes with CSA in Suppression of Graft-Versus-Host Reaction and Allogeneic Skin Graft Rejection", <i>Transplantation</i> , 60:362-368 (1995).					
	10.	Gennari, R. et al., "Granulocyte macrophage colony-stimulating factor improves survival in two models of gut-derived sepsis by improving gut barrier function and modulating bacterial clearance," <i>Annals of Surgery</i> 220:68-76 (1994).					
	11.	Grabstein, K.H. et al., "Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor," <i>Science</i> 264:965-968 (1994)					
	12.	Kasaian, M.T. et al., "IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity," <i>Immunity</i> 16:559-569 (2002).					
	13.	Kirchner, G.I. et al., "Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application," <i>Br. J. Clin. Pharmacol.</i> 46:5-10 (1998).					
	14.	Ma, H-L et al., "IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of INF- $\gamma$ ," <i>J. Immunol.</i> 171:608-615 (2003).					
	15.	Naito, K. et al., "Macrophage factors which enhance the mixed leukocyte reaction initiated by dendritic cells," <i>J. Immunol.</i> 142:1834-1839 (1989).					
	16.	Nastala, C.L. et al., "Recombinant IL-12 administration induces tumor regression in association with IFN- $\gamma$ production," <i>J. Immunol.</i> 153:1697-1706 (1994).					
	17.	Pahwa, R. et al. "Recombinant interleukin 2 therapy in severe combined immunodeficiency disease," <i>Proc. Natl. Acad. Sci. USA</i> 86:5069-5073 (1989).					
	18.	Patterson, S. et al., "Human invariant NKT cells are required for effective in vitro alloresponses," <i>J. Immunol.</i> 175:5087-5094 (2005).					

EXAMINER:	<i>NJH</i>	DATE CONSIDERED:	<i>1/17/07</i>
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).			
SV 2242374 v1			

EXAMINER: <i>N. Smith</i>	DATE CONSIDERED: <i>11/7/10</i>
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	
SV 2242374 v1	